Cargando…

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects

EDP‐297 is a farnesoid X receptor agonist under development for treating nonalcoholic steatohepatitis. The pharmacokinetic (PK), pharmacodynamic (PD), food effect, and safety were evaluated in a single ascending dose (SAD) and multiple ascending dose (MAD) phase I study. Healthy subjects received si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marotta, Christine, Ahmad, Alaa, Luo, Ed, Oosterhaven, Jart, van Marle, Sjoerd, Adda, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926082/ https://www.ncbi.nlm.nih.gov/pubmed/36369848 http://dx.doi.org/10.1111/cts.13453

Ejemplares similares

Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
por: Ahmad, Alaa, et al.
Publicado: (2022)

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist
por: Erstad, Derek J., et al.
Publicado: (2018)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1988)

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1982)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
por: Coakley, Eoin, et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
por: Younis, Islam R., et al.
Publicado: (2023)

Up the EDP pyramid : the complete job hunting manual for computer professionals /
por: French, Jack, 1932-
Publicado: (1981)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
por: Erken, Robin, et al.
Publicado: (2021)

Study protocol: efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): a randomised prospective open-label trial with blinded outcome assessment
por: Oosterhaven, Jart Ate Franke, et al.
Publicado: (2018)

The Role of Farnesoid X Receptor in Accelerated Liver Regeneration in Rats Subjected to ALPPS
por: Daradics, Noemi, et al.
Publicado: (2021)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Cost accounting in the EDP-supported chemical laboratory
por: Gibitz, H. J.
Publicado: (1983)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin
por: Lenicek, Martin, et al.
Publicado: (2020)

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
por: He, Handan, et al.
Publicado: (2023)

Caenorhabditis Intervention Testing Program: the farnesoid X receptor agonist obeticholic acid does not robustly extend lifespan in nematodes
por: Morshead, Mackenzie L, et al.
Publicado: (2020)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

297. Lactobacillus: Friend or Foe
por: Nwanyanwu, Chiemeziem, et al.
Publicado: (2020)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Presenteeism in a Dutch hand eczema population—a cross‐sectional survey
por: Oosterhaven, Jart A. F., et al.
Publicado: (2018)

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2021)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Health Tract, No. 297: Brain Work
Publicado: (1867)

Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
por: Finamore, Claudia, et al.
Publicado: (2023)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kuuooulmt18bb1a6gtj1h3do2j